Welcome
Support Centre
30 July 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Scottish Pre-Menopausal Chemo-Endocrine Trial
Source of recordUK Trials
ISRCTNISRCTN95231655
Date ISRCTN assigned19/08/2002
Local reference number(s)BR9401
Public titleScottish Pre-Menopausal Chemo-Endocrine Trial
Scientific title
AcronymNot Applicable
Disease/condition/study domainBreast
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Histologically confirmed invasive carcinoma of the breast
2. Pre-menopausal
3. No medical contraindications to treatment
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsFollowing surgery patients are randomised to one of four treatment arms:
1. Group A: Tamoxifen 20 mg daily for 5 years
2. Group B: Tamoxifen 20 mg daily for 5 years plus six cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy
3. Group C: Tamoxifen 20 mg daily for 5 years plus ovarian suppression
4. Group D: Tamoxifen 20 mg daily for 5 years, six cycles of CMF chemotherapy and ovarian suppression
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingScottish Cancer Therapy Network
Sponsor nameScottish Cancer Therapy Network
Sponsor detailsTrinity Park House
South Trinity Road
Edinburgh
United Kingdom
EH5 3SQ
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN95231655
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central